MARKET

PRTK

PRTK

Paratek Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.10
+0.04
+0.57%
After Hours: 7.10 0 0.00% 16:00 03/05 EST
OPEN
7.15
PREV CLOSE
7.06
HIGH
7.16
LOW
6.44
VOLUME
623.34K
TURNOVER
--
52 WEEK HIGH
8.75
52 WEEK LOW
2.500
MARKET CAP
324.05M
P/E (TTM)
-3.2346
1D
5D
1M
3M
1Y
5Y
Global Acute Bacterial Skin and Skin Structure Infections Treatment Market to Expand at 9.5% CAGR, Increasing Acute Bacterial Skin and Skin Structure Infections Incidence Identified as Chief Growth Driver, says Fortune Business Insights
Mar 05, 2021 (The Expresswire) -- The global “acute bacterial skin” and skin structure infections (ABSSSI) treatment market will derive growth from the...
The Express Wire · 18h ago
Insomnia Therapeutics Drugs Market Includes Top Countries Figures, Business Growth, Market Size, Swot Analysis, Business Opportunity, Applications, Trends and Forecast to 2027
The Express Wire · 1d ago
Paratek Pharmaceuticals (PRTK) Receives a Buy from Leerink Partners
In a report issued on February 25, Ami Fadia from Leerink Partners reiterated a Buy rating on Paratek Pharmaceuticals (PRTK), with a price target of
SmarterAnalyst · 1d ago
Insomnia Treatment Market Segmentation and Analysis by Recent Trends, consumption by Regional data, Development, Investigation, Growth by to 2026
Mar 03, 2021 (The Expresswire) -- Global “Insomnia Treatment Market” (2021-2026) to its vast repository and growth prospects of the market provides the...
The Express Wire · 2d ago
DJ Paratek Pharmaceuticals Initiated at Buy by Jefferies
Dow Jones · 3d ago
DJ Paratek Pharmaceuticals Price Target Announced at $15.00/Share by Jefferies
Dow Jones · 3d ago
--Analyst Actions: Jefferies Starts Paratek Pharmaceuticals at Buy with $15 Price Target
MT Newswires · 3d ago
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, governmen...
GlobeNewswire · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PRTK. Analyze the recent business situations of Paratek Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PRTK stock price target is 19.20 with a high estimate of 34.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 180
Institutional Holdings: 32.79M
% Owned: 71.83%
Shares Outstanding: 45.64M
TypeInstitutionsShares
Increased
33
1.69M
New
39
1.08M
Decreased
30
1.30M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Director
Michael Bigham
Chief Executive Officer/Chief Compliance Officer/Director
Evan Loh
Chief Financial Officer/Chief Accounting Officer
Sarah Higgins
Senior Vice President/Chief Compliance Officer/General Counsel/Secretary
William Haskel
Vice President
Adam Woodrow
Director
Rolf Hoffman
Other
Randall Brenner
Director
Rolf Hoffmann
Independent Director
Thomas Dietz
Independent Director
Timothy Franson
Independent Director
Kristine Peterson
Independent Director
Robert Radie
Independent Director
Jeffrey Stein
Declaration Date
Dividend Per Share
Ex-Div Date
--
Dividend USD 1.33
06/04/2014
About PRTK
Paratek Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections. Sarecycline is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Its other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class. These research stage programs include product candidates for multiple sclerosis, spinal muscular atrophy, systemic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel diseases.

Webull offers kinds of Paratek Pharmaceuticals Inc stock information, including NASDAQ:PRTK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRTK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRTK stock methods without spending real money on the virtual paper trading platform.